Updates On Relapsing-Remitting Multiple Sclerosis

Isaura Santos avatar

by Isaura Santos |

Share this article:

Share article via email


Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS).

Read the findings here: http://bit.ly/1LEWNQV

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here